15,048 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Acquired by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. bought a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 15,048 shares of the company's stock, valued at approximately $332,000.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Oarsman Capital Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $29,000. Marshall & Sterling Wealth Advisors Inc. bought a new stake in Teva Pharmaceutical Industries during the 4th quarter worth approximately $44,000. Ameliora Wealth Management Ltd. acquired a new stake in Teva Pharmaceutical Industries during the 4th quarter valued at $66,000. IFP Advisors Inc raised its position in Teva Pharmaceutical Industries by 96.1% in the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock valued at $88,000 after purchasing an additional 1,960 shares during the last quarter. Finally, Quadrant Capital Group LLC boosted its stake in Teva Pharmaceutical Industries by 27.7% in the fourth quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock worth $96,000 after purchasing an additional 949 shares in the last quarter. Institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Stock Up 2.8%

NYSE TEVA traded up $0.48 during trading hours on Monday, hitting $17.26. 9,478,222 shares of the company traded hands, compared to its average volume of 10,102,980. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The business's 50-day moving average is $15.52 and its 200-day moving average is $17.37. The stock has a market capitalization of $19.56 billion, a price-to-earnings ratio of -11.90, a P/E/G ratio of 1.44 and a beta of 0.62. Teva Pharmaceutical Industries Limited has a twelve month low of $12.47 and a twelve month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The business had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.99 billion. During the same period in the previous year, the company earned $0.48 earnings per share. The firm's revenue for the quarter was up 1.9% on a year-over-year basis. Sell-side analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on TEVA. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and upped their price target for the stock from $21.00 to $23.00 in a research report on Monday, May 12th. Truist Financial assumed coverage on Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a "buy" rating and a $25.00 target price for the company. Bank of America increased their price target on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. Finally, Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $24.50.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.